Metabolomic Analysis of the Effects of Phenylbutyrate (PB) in Patients with Mya
Closed Special Notice Posted
- Solicitation number
- 75N98026Q01076
- Agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Heart, Lung and Blood Institute, on behalf of the National Institutes of Health, issued a Notice of Intent on September 1, 2026 for a non-competitive purchase order to Metabolon, Inc. for metabolomic analysis services valued at $41.5 million, with responses due by September 8, 2026 at 10:00 a.m. EDT. The procurement is sole-source, justified by the requirement for analytical continuity with Metabolon's existing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) dataset; using an alternative vendor would introduce methodological variability and compromise scientific validity.
The work involves untargeted metabolomic profiling and bioinformatic analysis of 75 plasma samples from 30 ME/CFS patients (collected at baseline and after eight weeks of sodium phenylbutyrate treatment) and 15 healthy control volunteers. Metabolon will perform three comparative analyses: baseline ME/CFS versus healthy controls, post-treatment versus baseline ME/CFS, and post-treatment ME/CFS versus healthy controls. The base period runs from September 30, 2026 through September 29, 2027, with performance evaluation by the NHLBI Clinical Director.
Interested parties may submit capability statements, proposals, or quotations to James Hawkins (james.hawkins3@nih.gov) and Tara Knox (tara.knox@nih.gov). Submissions must include unit price, list price, shipping and handling costs, delivery period, payment discount terms, F.O.B. point, UEI, TIN, and business size certification. NAICS 621511 (Medical Laboratories); PSC Q301 (Reference Laboratory Testing).
Notice text
Metabolomic Analysis of the Effects of Phenylbutyrate (PB) in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Files
| File | Type | Posted |
|---|---|---|
| Notice_of_Intent_1.docx | DOCX document |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance | Office of Logisitics and Acquisition Operations | No set-aside | |
| Clinical Research Support and Collaboration for NHGRI Protocols | Office of Logisitics and Acquisition Operations | Total Small Business |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity